Buy the Dip Monday: The 40% Drawdown Chip Stock With Insiders Buying and a 900% Analyst Target
Top 5 Pixie Picks
Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Value stocks.
Sign in →6. GSK plc (GSK)
P/E: 13.0 | Earnings yield: 7.7% | 52w drawdown: -19.1%
The pharma company trades at 13× earnings with a 4.8% FCF yield, 20% ROIC, and 72% gross margin while delivering 4.1% revenue growth. The 14.3 normalized P/E and 19% drawdown place the valuation near the middle of the historical range, with analysts targeting 16% upside to $57.94.
GSK's hepatitis B treatment pipeline is flagged as a potential £2 billion opportunity in recent news coverage, adding a late-stage catalyst to the existing vaccine franchise. The 3.6% dividend yield and 1.4% shareholder yield provide downside support while the pipeline matures.
The 117% debt-to-equity ratio and 18.7× EV/EBITDA signal the market is pricing in commercial execution risk on the hepatitis franchise, even as the core business delivers consistent mid-single-digit growth.
7. First Solar, Inc. (FSLR)
P/E: 13.2 | Earnings yield: 7.6% | 52w drawdown: -36.3%
The solar manufacturer trades at 13.2× earnings with a 5.4% FCF yield, 16.7% ROIC, and 24% revenue growth year over year. The 13.5× EV/EBITDA and 36% drawdown price in solar sector volatility while analysts see 19% upside to $243.59.
Three insiders filed Form 4 sales over the past 30 days: Markus Gloeckler, Jason Dymbort, and Samantha Sloan each sold shares in August and early September. One insider sold 50,930 shares net over the past six months, signaling caution even as the company delivers double-digit revenue growth.
The 8.5% short interest and insider selling flag concern over solar policy risk and panel pricing pressure, even as the revenue trajectory remains intact and the valuation sits at a 36% discount to the 52-week high.
8. Barrick Gold Corporation (GOLD)
P/E: 15.0 | Earnings yield: 6.7% | 52w drawdown: -30.8%
The gold miner trades at 15× earnings with a 10.6% FCF yield and 13% revenue growth year over year while analysts see 40% upside to $64.75. The 10.6 normalized P/E places the current 15× multiple above the historical average, yet the FCF yield of 11% and 31% drawdown suggest the market is pricing in gold price risk despite the operational momentum.
Three insiders filed Form 4 buys in August and early September: Michael Clark and David Larimer each bought on August 19, while Kelly Gold added shares on September 2. The 1.7% dividend yield and insider activity provide downside support while the gold price cycle matures.
The 255% debt-to-equity ratio, 14.9% short interest, and 1.9% gross margin flag operational leverage risk, even as the gold price environment remains supportive and insiders signal confidence in the current valuation.
What to Watch
- October 20 (EQT earnings): The natural gas producer reports with estimates of $0.49 EPS on $2 billion revenue; a beat confirms the 60% revenue growth trajectory and validates the CEO's August insider buy.
- October 22 (AMAL earnings): The community bank reports with estimates of $1.08 EPS; guidance will clarify whether the near-high valuation is justified or if the analyst downgrade to $46 was prescient.
- October 28 (KLAC earnings, GSK earnings): The chip toolmaker reports $1.18 EPS on $4 billion revenue estimates while GSK reports $1.35 EPS on $8.9 billion estimates; both will test whether the 40% and 19% drawdowns are pricing in real deterioration or temporary volatility.
- October 29 (CNX earnings, FSLR earnings): The natural gas producer reports $0.60 EPS while the solar manufacturer reports $4.67 EPS; revenue guidance will clarify the sustainability of the 49% and 24% growth rates driving the current value setups.
Go Deeper
The value screener isolates stocks trading below historical valuation multiples with strong cash flow generation, analyst upside, and insider validation.
Pro-only analytics
Named tickers from this article open in the app with Pro or an active trial.
Sign in →Stock Pixie Pro
See the full Rising Value screen — every pick, every metric, every day.
The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.
Start your free trial →Or start with the free Market Brief Digest
Where the market stands before the open, in plain language, every trading day. No account needed.